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AbstrAct:
Tumor initiating or cancer stem cells (CSCs) are suggested to be responsible for 
tumor initiation and growth. Moreover, therapy resistance and minimal residual 
disease are thought to result from selective resistance of CSCs. Isolation of CSCs 
from  colon  carcinomas  can  be  accomplished  by  selection  of  a  subpopulation 
of  tumor  cells  based  on  expression  of  one  or  multiple  cell  surface  markers 
associated  with  cancer  stemness,  like  CD133,  CD44,  CD24,  CD29,  CD166  and 
Lgr5. Identification of colon CSCs will lead to a better rational for new therapies 
that  aim  to  target  this  fraction  specifically.  In  this  review,  we  analyze  known 
markers  used  for  selection  of  colon  CSCs  and  their  potential  function  in  CSC 
biology. Moreover, we discuss potential targeting strategies for eradicating CSCs 
specifically in order to develop more effective therapeutic strategies as well as to 
address more fundamental questions like the actual role of CSCs in tumor growth.
INtrODUctION
Tumors have long been viewed as a population in 
which all cells have the equal propensity to form new 
tumors, the so called conventional stochastic model. 
New insight was obtained when a small subset was 
discovered in acute myeloid leukemia (AML) [1,2] that 
retained the ability to serially transplant. Since then, a 
new hierarchical model was born, claiming that tumors 
consist of a small fraction of so called tumor initiating 
cells, also referred to as cancer stem cells (CSCs) that are 
capable of initiating and maintaining tumor growth and 
a large fraction of more differentiated cells, which are 
incapable of maintaining tumor growth. After discovering 
these CSCs in hematological malignancies, their presence 
was also found in several solid tumors, like breast [3-5], 
lung [6], ovarian [7], liver [8], prostate [9], pancreas [10], 
skin [11], brain [12,13] and colon cancer [14-17], which 
will be the focus of this review. To prove the presence 
of CSCs within a tumor, several main criteria have been 
established  by  the  scientific  community:  firstly,  CSCs, 
identified  by  a  specific  cell  surface  marker,  should  be 
able to serially transplant the tumor in vivo; secondly, 
the tumors that grow out from the CSCs should resemble 
the original malignancy; thirdly, CSCs should be able 
to differentiate in marker-negative cells. To determine 
the CSC-frequency, in vivo limiting dilution assays 
(LDA) are performed, which means that several dilutions 
and multiple replicates of marker-positive or marker-
negative cancer cells are injected subcutaneously in 
(immunodeficient) mice. Cell surface markers that have 
been used for identification of colon CSCs are CD44 [18-
20], CD133 [14-17], CD166 [20], whereas expression of 
CD24 [17], CD29 [17] and Lgr5 [21] has also been found 
in colon CSCs. More functional markers like Wnt activity 
[22] and ALDH1 activity [23] have been exploited as well. 
Through  identification  of  CSCs  in  colon  cancer,  more 
can be learned about the role of these cells in initiating 
and driving tumor growth. In this review, we examine 
the markers used for colon CSC identification and their 
possible function, as well as methods to target these CSCs 
specifically,  both  at  therapeutic  as  wells  as  at  a  more 
fundamental level. Oncotarget 2010; 1:  387 - 395 388 www.impactjournals.com/oncotarget
MArKErs UsED tO IDENtIFY cOLON 
csc 
The five-transmembrane glycoprotein CD133 is one 
of the first colon CSCs markers identified and its use as a 
CSC marker has been controversial since then. Selecting 
colon cancer cells based on positivity for AC133, an 
epitope on the CD133 protein, identifies the tumorigenic 
and clonogenic population [14-17,24]. On the other hand, 
CD133 expression was found throughout the normal 
gastro-intestinal tract and therefore does not seem to be 
restricted to the stem cell compartment [25,26]. In addition, 
CD133+ as well as CD133- metastatic colon cancer cells 
were shown to be able to form new tumors, indicating 
that usage of CD133 as a CSC marker is questionable 
[26]. In this light, it is important to note two things. First, 
CD133 expression can be regulated by hypermethylating 
the CpG island in the CD133 promoter region, an event 
that frequently occurs in higher grade tumors and results 
in CD133 downregulation independent from its potential 
role in CSCs [27]. Secondly, the CD133 mRNA or surface 
expression is not changed during differentiation [24,28]. 
Instead the AC133 epitope is masked and inaccessible for 
the antibody in differentiated colon cancer cells, likely 
due to a difference in the glycosylation status and folding 
of the protein [24]. In agreement, the epitope can be re-
exposed by certain treatments, potentially explaining 
different outcomes in immunohistochemical stainings 
[24,26]. Although CD133 can be used as a CSC marker, it 
therefore should be done with caution.
The transmembrane glycoprotein CD44 has been 
used as a marker to isolate CSCs from multiple solid 
tumors, such as breast [3], head and neck [29], pancreas 
[30] and also colon cancer [31].Colon cancer cells sorted 
for CD44+ displayed high tumorigenicity, especially in 
combination with CD133-positivity, whereas CD44- cells 
could  not  form  new  tumors  in  immunodeficient  mice 
[19,20]. CD44 can also be used in combination with 
mesenchymal stem cell marker CD166 (also referred to 
as ALCAM). CD44+CD166+ colon cancer cells display 
a higher ability to form tumors in immunodeficient mice 
as compared to CD44+CD166-, CD44-CD166- or CD44-
CD166- cell populations [20], making this an useful 
combination for the identification of colon CSCs. 
In  normal  colon,  integrin  subunit  β1  (CD29) 
expression was observed in the lower parts of the crypt and 
thereby seems to mark a more stem/progenitor cell type 
[32]. Moreover, the combination of CD24highCD29high was 
suggested to identify the tumor initiation fraction in mouse 
colon carcinomas (R.Fodde, personal communication, 
[17]). Indeed, human colon CSCs were found to express 
high levels of CD24 and CD29 [17], suggesting that these 
markers can also identify human colon CSCs, although 
further evidence is necessary.
Not only cell surface markers, but also activity of 
certain pathways or enzymes can mark stemness. For 
instance,  normal  colon  stem  cells  can  be  identified  by 
the activity of aldehyde dehydrogenase 1 (ALDH1), a 
detoxifying enzyme that oxidizes intracellular aldehydes, 
therefore involved in the resistance to alkylating enzymes. 
ALDH1 activity can be measured by a method using 
dansyl aminoacetaldehyde and staining for ALDH1 
revealed a few positive cells in the crypt [23]. In addition, 
when colon cancer cells were selected for ALDH1 activity 
using Aldeflour, ALDH1+ cells were able to initiate new 
tumors whereas ALDH1- cells were not [23], indicating 
that ALDH1 activity can be used as a colon CSC marker.
Besides the ALDH1 activity, recent evidence 
indicates that Wnt signaling activity can serve as a 
functional designation of colon CSCs [22]. Activating 
mutations in the Wnt pathway are pivotal in the initiation 
of the majority of colon cancers. However, recent evidence 
indicates that a clear heterogeneity in Wnt signaling still 
exists within separate cells within a colon cancer [33,34]. 
Interestingly, colon cancer cells with high Wnt activity 
express stem cell markers and have higher clonogenic 
capacity and tumorgenicity, whereas cells with low Wnt 
activity express higher levels of differentiation markers 
and are unable to give rise to new tumors [22]. In this light, 
it is interesting to note that Lgr5 is a Wnt target gene [35], 
exclusively expressed on the normal intestinal stem cells 
[36] and could thus also be a CSC marker. Interestingly, 
human colon CSCs were found to express Lgr5 [22]. In 
addition, tumorigenesis in mice is much more effective in 
Lgr5+ stem cells as compared to more differentiated cells 
[21]. However, formal evidence that Lgr5 identifies colon 
CSCs is still lacking and awaits the generation of reliable 
antibodies that can be used to isolate Lgr5+ tumor cells. 
FUNctION OF csc MArKErs AND 
tHEIr rELEVANcE tO csc bIOLOGY
Most of the markers used for colon CSC isolation 
are chosen either because they are expressed in normal 
stem cells or were found to identify CSCs in other 
malignancies, either hematological or solid. The 
disadvantage of choosing markers in this fashion is that 
the functional effect of expression of the marker in CSCs 
is usually unknown. Also, the expression level (high 
versus low) used for identifying CSCs sometimes differs 
between tissue types [37]. Therefore, the choice of these 
markers is largely based on an “educated guess”.  
For instance, breast cancer cells expressing either no 
or low levels of single chain sialoglycoprotein CD24 in 
combination with CD44-positivity have been identified 
as CSCs [3], whereas in pancreas and colon, the CD24high 
cells were shown to contain the tumor-initiating fraction 
[10,17]. CD24, first described as a cell surface marker 
for several haematopoietic cell populations, is known 
to play a role in cell-cell interaction [38,39], adhesion 
and proliferation [40,41]. Many cancers were found to 
over-express CD24 [42-44], indicating that the protein Oncotarget 2010; 1:  387 - 395 389 www.impactjournals.com/oncotarget
can play an important role in tumorigenesis. However, 
its  role  in  CSC  biology  remains  undefined,  especially 
because the expression level by which the CSC should 
be selected differs between tissue types. Together with 
CD24, CD29-positivity has been used to identify the 
colon CSC population [17]. Cell surface receptor CD29, 
like CD24, mediates cell to extracellular matrix adhesion 
and can promote cancer progression by inducing invasion, 
migration and metastasis [45,46]. Its function in CSC 
biology has not been studied yet.
The choice for CD166 as a marker for CSCs was 
based on the heterogeneous expression of CD166 in 
colon  carcinoma  in  combination  with  the  finding  that 
its expression correlates with a poor clinical outcome in 
colorectal cancer (CRC) patients [47]. Also CD166 is 
involved in regulation the formation of cell-cell contacts 
[48,49]. Even though the function of the debated CSC 
marker CD133 remains unknown, its presence in plasma 
membrane protrusions [50,51] as well as its ability to 
interact with plasma membrane cholesterol [52] suggests 
that the protein might play a role in establishing and 
maintaining plasmamembrane protrusions. This suggests 
that CD133 could play a role in cell polarity and migration 
[53] via cell-cell and cell-matrix interactions. In contrast, 
knockdown of CD133 in colon cancer cell lines or 
primary colon cultures did not influence the proliferation, 
migration, invasion, clonogenic and tumorigenic 
formation capacity [19,54], indicating that the protein 
itself is not required for maintenance of the CSC state.
Interestingly, most of the CSC markers were chosen 
based on expression level instead of potential function in 
CSCs and most of them seem to play a role in inducing and/
or maintaining cell-cell or cell-matrix contact. A worrying 
aspect of such CSC markers is that enhanced attachment 
could in part explain why cells expressing these markers 
are more capable of growing in a new environment. 
Xenograft growth is currently the accepted/compulsory 
method to prove cancer stemness, but identification of 
adherence factors as CSC markers could simply be a 
reflection of the need for adherence in the assay itself. 
For this reason, it would be favorable to identify CSCs by 
markers that have a clear function in CSC biology.
CSC marker CD44 is one of those markers that might 
have a more functional role in CSC biology. For instance, 
knockdown of CD44 in primary colon cancer cell lines 
reduces clonogenicity in vitro and tumorgenicity in vivo 
[19]. CD44 is known to be involved in many cellular 
processes like survival, growth, differentiation and 
survival. As an important adhesion molecule, CD44 plays 
a major role in cancer cell migration. Several different 
splice variants are known for CD44. Interestingly, the 
ectodomain of one of its variants, CD44v6, was found 
to be required for c-Met activation in several tumors 
[55,56]. Moreover, hepatocyte growth factor (HGF), the 
ligand for c-Met, can restore the CSC phenotype in more 
differentiated colon cancer cells [22] and seems to play a 
major role in maintaining a CSC state. Therefore, CD44 
itself may have a role in regulating stemness in CSCs and 
thus may be a functional cell surface CSC marker. 
A more functional read-out of stemness in cancer 
cells is the activity of the ALDH1 enzyme. This enzyme, 
which  oxidizes  intracellular  aldehydes,  identifies  the 
cells that are more resistant to alkylating agents [57-59]. 
Therefore, cells that have high ALDH1 activity are better 
protected against oxidative insults. In concordance, CSCs 
are thought to be more resistant to therapeutic agents 
[60-67]. In addition, ALDH1 convert retinol to retinoic 
acid. The effect of retinoids on cells is very dependent 
on the differentiation stage in which there are, but in 
hematopoietic stem cells (HSCs), retinoids have been 
shown to enhance self-renewal [56,68]. Therefore, high 
ALDH1 activity can have a dual role in maintaining a 
CSC state.
Another functional marker for CSCs, as recently 
identified  by  our  group,  is  Wnt  activity.  For  normal 
intestinal stem cells, Wnt activity is essential for 
maintaining stemness and crypt survival [69,70]. 
Important players in the Wnt signaling cascade, the 
tumor suppressor adenomatous polypolis coli (APC) and 
ß-catenin, are frequently mutated in colon cancer. As a 
consequence, ß-catenin will not be degraded by the APC 
complex and accumulation of ß-catenin in the nucleus 
and consequent activation of Wnt target genes occurs 
[71]. However, despite the presence of these activating 
mutations, tumors display heterogeneous expression 
of nuclear ß-catenin [33,34], indicating that alternative 
regulation of Wnt signaling is taking place. Cells with 
high Wnt activity represent the CSCs within the tumor. 
Importantly, extrinsic cues, like HGF produced by 
surrounding myofibroblasts in the stroma, were shown to 
modulate the Wnt signaling activity as well, providing a 
connection between the stroma and the CSCs [22]. 
As described above, some functional markers have 
been  identified,  but  more  will  be  needed.  In  addition, 
the currently used cell surface markers should be more 
investigated to discover their role in CSC biology.
WHY tArGEt csc?
Reliable markers that identify CSCs will pave the 
way to better understanding of signaling pathways and 
other regulatory mechanisms that determine stemness 
and differentiation of CSCs. As CSCs are considered 
to be the driving force behind tumor growth, therapies 
will have to focus on strategies that include targeting of 
CSCs. However, radio- or chemotherapy of cancer often 
incompletely eradicates tumor cells [60-67] and this is 
thought to be due to a selective survival advantage of 
CSCs, which could explain relapse of the tumor after 
many years. For example, studies have shown that 
colon CSCs are more resistant to treatment with 5-FU or 
oxaliplatin [16,72]. In addition, when CRC cell lines were Oncotarget 2010; 1:  387 - 395 390 www.impactjournals.com/oncotarget
treated with 5-FU or oxaliplatin in vitro, an increase in 
CD133+CD44+ cells was observed [73], indicating that 
the CSC fraction was enriched and thus resistant to these 
therapeutics. Recurrence of colon cancer and appearance 
of distant metastasis many years after initial treatment are 
therefore hypothesized to be caused by residual CSCs. So, 
by targeting the CSCs specifically, it should be possible 
to obtain more complete degeneration of the tumor. 
Obviously, combination therapies that target both CSCs 
and more differentiated progeny will in the end be more 
efficient for use in the clinic. Especially as new studies have 
shown that factors produced by the microenvironment can 
revert differentiated cells back to a more stem cell-like 
state [22], indicating that killing the CSCs alone might not 
be sufficient to diminish tumor growth. 
From  a  more  scientific  perspective,  killing  CSCs 
selectively in growing tumors could validate the currently 
favored hypothesis that CSCs are the only clonogenic 
cells within tumors. As indicated above, the current 
xenotransplantation assays define the cells that are capable 
of initiating tumor growth in immunocompromised mice. 
However, it is currently unclear whether these cells are 
also required to maintain growth of an existing tumor. 
Therefore, ablating CSCs selectively in growing tumors 
in vivo will give more insight into their biological role in 
tumors as well as their flexibility/plasticity. 
tArGEtING csc MArKErs
A strategy to target CSCs is exploiting the presence 
of their cell surface markers. Membrane proteins can be 
targeted directly or used to internalize a death-inducing 
compound. For instance, in AML blasts, the first strategy 
was employed. One of the problems in AML is that blast 
cells are arrested in more progenitor-like state and do not 
fully differentiate. The CSC marker CD44 is known to 
play a role in normal myeloid differentiation, as this can be 
inhibited by CD44 blocking antibodies [74,75]. Treatment 
of AML blasts in vitro with CD44-activating monoclonal 
antibodies relieves the differentiation blockade. Moreover, 
in some cases, the CD44-activating antibodies could 
decrease proliferation and increase apoptosis of the blasts 
[76]. Additionally, leukemic stem cells (LSCs) could be 
killed in vivo when mice transplanted with AML cells 
were treated with the activating CD44 antibody H90. 
Ligation of CD44 inhibited the migration of LSCs to 
their niche, but also affected LSCs intrinsically, because 
repopulation capacity was severally affected afterwards 
[16,77]. Combined, this suggests that targeting CD44 
could be a good strategy to attack CSCs.
The use of cell surface markers to guide toxic insults 
was employed by Wang et al. who targeted the CSC 
marker CD133 in glioblastoma (GBM). They conjugated 
an anti-CD133 antibody to single walled carbon nanotubes 
(SWNTs), which were developed to serve as an alternative 
option for localized hyperthermia treatment in comparison 
to gold-based nanomaterials [78,79]. Exposing CD133+ 
GBM cells to these anti-CD133-SWNTs induced 
internalization of the SWNTs whereas CD133- cells did 
not take up the SWNTs. Exposing the cells to 808-nm 
near-infrared (NIR) laser light induced specific killing of 
the CD133+ cells. In vivo treatment of CD133+-SWNT-
treated GBM cells by NIR laser induced photothermolysis 
also significantly reduced tumor growth [80].
tArGEtING DIFFErENtIAtION AND 
sUrVIVAL sIGNALING IN csc
Since conventional therapies do not suffice in killing 
all tumor cells, the addition of a sensitizer targeting a 
pathway responsible for resistance of CSCs or inducing 
differentiation could overcome this problem. For instance, 
colon carcinomas are producing IL-4 that is responsible 
for upregulation anti-apoptotic molecules in these tumors. 
Inhibiting IL-4 by blocking antibodies sensitizes the cells 
for killing by 5-FU and oxaliplatin [16]. Also induction 
of differentiation in colon CSCs by exposing these cells 
to Bone Morphogenetic Protein 4 (BMP4), which can 
initiate a differentiation program as well as mediate 
apoptosis [81], sensitizes colon cancer cells to killing with 
5-FU or oxilaplatin in vivo, resulting in complete and long 
term regression of colon xenografts [82]. 
Also other signaling pathways were found to 
be involved in maintaining CSCs and therefore are 
thought to be essential for tumor growth. For instance, 
Hedgehog(HH) signaling is suggested to play a role in 
CSCs of several tumor types, like glioblastoma [83] , breast 
cancer [84], pancreatic cancer [85], multiple myeloma 
[86] and colon cancer [87]. To activate HH signaling, 
HH binds to the receptor Patched leading to the release of 
Patched-mediated repression of Smoothened (SMO) and 
to activation of the downstream Gli transcription factor 
family. In CD133+ advanced/metastatic colon cancer 
cells, higher levels of Gli1, a measure for HH activity, 
were found, compared to CD133- cells. Inhibition of HH 
signaling in primary colon cancer cell lines by knockdown 
of SMO reduces proliferation and induces apoptosis in 
vitro. In addition, in vivo tumor growth is abrogated by 
inhibition of HH signaling, because of reduced survival 
of CSCs [87].
Also  Notch  signaling  has  been  identified  as  an 
essential pathway for the maintenance of the stem-cell 
like state of colon CSCs [88]. An important component 
of the Notch pathway is delta-like 4 ligand (DLL4). 
By inhibiting DLL4 with human monoclonal antibody 
21M18 in colon carcinoma xenografts, the tumor growth 
as well as the CSC frequency, measured by the amount 
of ESA+CD44+CD166+ cells is decreased compared 
to control. Interestingly, even though treatment of the 
xenografts with irinotecan, a chemotherapeutic often used 
in colon cancer, slowed down tumor growth, the frequency 
of ESA+CD44+CD166+ cells and the clonogenicity was Oncotarget 2010; 1:  387 - 395 391 www.impactjournals.com/oncotarget
increased. Combination treatment of irinotecan with 
anti-hDLL4 reduced again the tumor growth and stem 
cell frequency, at even higher levels than the anti-DLL4 
treatment alone [89]. This indicates that inhibiting Notch 
signaling reduces CSC frequencies and sensitizes tumor 
cells for irinotecan treatment. 
GENE sUIcIDE tHErAPY FOr 
tArGEtING csc As PrOOF OF 
PrINcIPLE
As mentioned above, many studies support the 
existence of CSCs. However, sorting techniques to isolate 
CSCs, as well as xenotransplantation assays needed to 
prove stemness, also disrupt the tumor microenvironment 
and likely introduce a selection bias. Therefore, it is 
difficult to prove that CSCs unequivocally exist. To study 
the actual role of CSCs in tumor growth in vivo, gene 
suicide  therapy  specifically  against  CSCs  are  needed. 
Using this strategy, suicide genes like the herpex simplex 
virys thymidine kinase (TK), diphtheria toxin or pro-
apoptotic genes are placed under the regulation of a CSC-
specific promoter. The activity of the suicide genes is then 
regulated either by a prodrug such as ganciclovir for TK 
or by combination with a genetic control mechanism, for 
instance using a stop cassette flanked by loxP sites so that 
suicide gene expression can be induced upon removal of 
the floxed cassette. CSCs can then be specifically targeted 
and the effect on tumor growth can be studied. 
A method to target CSCs by a suicide gene that is 
independent of cell division is making use of Diphtheria 
Toxin A (DTA) gene. The DTA gene encodes for an 
adenosine diphosphate (ADP) ribosyltransferase which is 
responsible for ADP-ribosylation of elongation factor 2. 
The effect of this ribosylation is that protein synthesis is 
inhibited and cell death is induced [90]. The advantage 
of this system is that only one molecule of DTA per cell 
is sufficient to induce cell death [91]. A recent study was 
published that made use of expressing DTA under a CSC 
marker. In this study, mouse glioma-initiating cells (GICs) 
were generated by overexpressing SV40 Large T antigen 
and oncogenic Ras in neural mouse stem cells. To be able 
to specifically eradicate GICs, these cells were genetically 
modified to carry the DTA gene by a floxed-lacZ cassette 
under the control of the CD133 locus as well as a CreER 
construct under the expression of a ubiquitous promoter. 
Injection of these GICs resulted in tumor formation that 
matched human glioma phenotypically. In addition, the 
tumors displayed a subset of cells that were CD133+. 
When the GICs were ablated from CD133+ cells by 
addition of tamoxifen in vitro and subsequently injected 
in vivo, the tumor formation was not affected, showing 
that CD133+ cells are not required for tumorigenesis in 
this model [92]. Whether this is also the case for colon 
cancer growth remains to be established. However, these 
findings could significantly change the CSC dogma and 
suggest that CSC-specific therapies may not be sufficient 
to treat cancer.
cONcLUDING rEMArKs
Several markers have been used to identify colon 
CSCs, such as CD24, CD29, CD133, CD166, but the 
function of these proteins in CSC biology has not yet 
been  clarified.  Interestingly,  these  CSCs  markers  are 
involved in cellular adherence and since the golden 
standard in this field to identify CSCs by their capacity 
to recapitulate the original tumor when xenotransplanted 
into immunocompromised mice, the presence of 
adherence markers can be exploited by these cells to 
form new tumors. Therefore, the role of CSCs markers 
in maintaining a stem cell state should be investigated 
and more functionally important markers should be 
identified, like CD44, ALDH1 activity and Wnt signaling. 
Combination of previously known and new markers could 
lead  to  more  directed  therapy  that  specifically  targets 
CSCs. At therapeutic and scientific level, specific targeting 
of CSCs could give more insight into how and whether 
these CSCs maintain tumor growth and in which way 
we can eradicate them. Studies that target CSCs within 
a growing tumor by suicide gene therapy could give not 
only more insight into their ability to maintain tumor 
growth, but also into their flexibility/plasticity within a 
tumor. This is especially relevant as an increasing number 
of studies indicate a role for the microenvironment/niche 
in the maintenance CSCs, which could even be dominant. 
Although this role is currently ill-defined it could provide 
novel clues for CSC biology as well as therapy.
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